Studied for
2 endpoints · 2 findings · 1 paper · 2 null
- Interleukin-6 concentrationno detected effectGrade B, Likely. Human evidence with one recorded weakness, or capped at B by its design or by unread numbers.
- Tumour necrosis factor alpha concentrationno detected effectGrade B, Likely. Human evidence with one recorded weakness, or capped at B by its design or by unread numbers.
What the evidence says
How to read these marks2 findings · 2 endpoints · 1 paper · 2 null · by grade
Every finding here is a null result.
What did not
2 findings
No detected effect on tumour necrosis factor alpha concentration
LikelyGrade B, Likely. Human evidence with one recorded weakness, or capped at B by its design or by unread numbers.FindingNull result“Overall, the pooled results suggest that sertraline did not significantly alter circulating levels of IL-6, IL-10, or TNF-α across the included studies.”
Quoted verbatim from Sertraline as an Antidepressant and Inflammatory Cytokines in Depressive Disorders: A Systematic Review and Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials.. - Study
- meta-analysis
- Population
- adults treated with sertraline for depressive disorders, pooled across trials with mixed comorbidities including coronary heart disease and chronic kidney disease
Sertraline as an Antidepressant and Inflammatory Cytokines in Depressive Disorders: A Systematic Review and Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials.2026PMID:42646594Permalink
No detected effect on interleukin-6 concentration
LikelyGrade B, Likely. Human evidence with one recorded weakness, or capped at B by its design or by unread numbers.FindingNull result“Overall, the pooled results suggest that sertraline did not significantly alter circulating levels of IL-6, IL-10, or TNF-α across the included studies.”
Quoted verbatim from Sertraline as an Antidepressant and Inflammatory Cytokines in Depressive Disorders: A Systematic Review and Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials.. - Study
- meta-analysis
- Population
- adults treated with sertraline for depressive disorders, pooled across trials with mixed comorbidities including coronary heart disease and chronic kidney disease
Sertraline as an Antidepressant and Inflammatory Cytokines in Depressive Disorders: A Systematic Review and Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials.2026PMID:42646594Permalink
Papers screened
629 papers
- Compound
- sertraline
- Screened
- 629
- Admitted
- 1
- Discarded
- 5
- Not read
- 623
- Showing
- 200 of 629
Produced a finding1 paper
- PMID:426465942026-09-29
Discarded: an endpoint this vocabulary does not hold3 papers
- PMID:25589155no claim extracted — no_outcome_node — measured: maternal-to-infant serum sertraline transfer via breastfeeding, correlation of paired maternal/infant serum concentrations | infant serum sertraline concentration relative to maternal serum concentration during breastfeeding2026-09-29
- PMID:27770542no claim extracted — no_outcome_node — measured: congenital anomalies (cardiovascular-related malformations; atrial/ventricular septal defects) in infants following first-trimester sertraline exposure | congenital cardiovascular malformation incidence in infants, pooled odds ratio from cohort studies2026-09-29
- PMID:31169738no claim extracted — no_outcome_node — measured: intravaginal ejaculation latency time (IELT), patient-timed | intravaginal ejaculation latency time (IELT), stopwatch- or patient-timed change from baseline2026-09-29
Discarded: another reason, stated per paper2 papers
- PMID:30544429no claim extracted — cause not determined2026-09-29
- PMID:34992673no claim extracted — cause not determined2026-09-29
Not read yet623 papers
- PMID:102076632026-09-29
- PMID:103473382026-09-29
- PMID:104405232026-09-29
- PMID:105378662026-09-29
- PMID:108021322026-09-29
- PMID:108902612026-09-29
- PMID:112815002026-09-29
- PMID:114369532026-09-29
- PMID:118168662026-09-29
- PMID:118186772026-09-29
- PMID:119790642026-09-29
- PMID:120175132026-09-29
and 611 more.
Measured, not recorded
- Compound
- sertraline
- Endpoints measured
- 32 endpoints
- Recorded as a finding
- No
Show what was measured
correlation between maternal and infant serum desmethylsertraline concentration
increases, Fisher's Z=0.391, 95% CI (0.071, 0.711), p = 0.017
Maternal and infant desmethylsertraline levels were significantly correlated in these studies [Fisher's Z=0.391, p=0.017, 95% CI (0.071, 0.711)] and zero was not included in the confidence interval.
PMID:25589155 · both readings recorded this
correlation between maternal and infant serum sertraline concentration
no effect, Fisher's Z=0.048, 95% CI (-0.154, 0.251), p = 0.639
The mean correlation depicting the relationship between maternal and infant sertraline concentrations in mother-baby dyads was small and not significant [Fisher's Z=0.048, p =0.639, 95% CI (−0.154, 0.251)] with confidence intervals including zero.
PMID:25589155 · both readings recorded this
correlation between maternal and infant serum sertraline concentration in breastfeeding mother-infant dyads, Fisher's Z transformed Pearson correlation
no effect, Fisher's Z=0.048, 95% CI (-0.154, 0.251), p = 0.639
Not recorded as a finding: this platform holds no node for the endpoint
The mean correlation depicting the relationship between maternal and infant sertraline concentrations in mother-baby dyads was small and not significant [Fisher's Z=0.048, p =0.639, 95% CI (−0.154, 0.251)] with confidence intervals including zero.
PMID:25589155 · one of two readings recorded this
correlation between maternal and infant serum sertraline concentration in breastfeeding mother-infant dyads, meta-analytic Fisher's Z
no effect, Fisher's Z=0.048, 95% CI (-0.154, 0.251), p = 0.639
Not recorded as a finding: this platform holds no node for the endpoint
The mean correlation depicting the relationship between maternal and infant sertraline concentrations in mother-baby dyads was small and not significant [Fisher's Z=0.048, p =0.639, 95% CI (−0.154, 0.251)] with confidence intervals including zero.
PMID:25589155 · one of two readings recorded this
correlation between maternal and infant serum sertraline+desmethylsertraline sum concentration
increases, Fisher's Z=0.367, 95% CI (0.080, 0.654), p = 0.012
The sum of sertraline and desmethylsertraline was significantly correlated between mothers and infants in these studies [Fisher's Z=0.367, p=0.012, 95% CI (0.080, 0.654)] and zero was not included in the confidence interval.
PMID:25589155 · one of two readings recorded this
Correlation between maternal and infant serum sum of sertraline plus desmethylsertraline concentration
increases, Fisher's Z=0.367, 95% CI (0.080, 0.654), p = 0.012
The sum of sertraline and desmethylsertraline was significantly correlated between mothers and infants in these studies [Fisher’s Z=0.367, p=0.012, 95% CI (0.080, 0.654)] and zero was not included in the confidence interval.
PMID:25589155 · one of two readings recorded this
adverse events
no effect, RR 0.94; 95% CI 0.83-1.06, p = 0.33
no significant difference between sertraline and control groups in the morbidity of adverse events (RR 0.94; 95% CI 0.83-1.06; P = .33 >0.05).
PMID:30544429 · one of two readings recorded this
gastrointestinal upset (adverse event)
increases, RR 2.71, 95% CI 1.39 to 5.28, p = 0.004
Among them, a significant increased risk of gastrointestinal upset was observed in pooled results of 8 studies (RR 2.71, 95%CI 1.39 to 5.28, P =.004).
PMID:31169738 · one of two readings recorded this
Gastrointestinal upset incidence (adverse event)
increases, RR 2.71, 95% CI 1.39 to 5.28, p = 0.004
Among them, a significant increased risk of gastrointestinal upset was observed in pooled results of 8 studies (RR 2.71, 95%CI 1.39 to 5.28, P =.004).
PMID:31169738 · one of two readings recorded this
intravaginal ejaculation latency time (IELT)
increases, SMD 2.14, 95% CI 1.20 to 3.08, n = 830
Meta-analysis showed that sertraline can prolong the IELT (changes of IELT, SMD 2.14, 95% CI 1.20 to 3.08, P <.00001; I 2 = 96%).
PMID:31169738 · both readings recorded this
intravaginal ejaculation latency time (IELT), meta-analysed as standardised mean difference across trials of sertraline versus placebo/blank control
increases, SMD 2.14, 95% CI 1.20 to 3.08, n = 830
Not recorded as a finding: this platform holds no node for the endpoint
Meta-analysis showed that sertraline can prolong the IELT (changes of IELT, SMD 2.14, 95% CI 1.20 to 3.08, P <.00001; I 2 = 96%).
PMID:31169738 · one of two readings recorded this
intravaginal ejaculation latency time (IELT), patient-timed, meta-analytically pooled as SMD
increases, SMD 2.14, 95% CI 1.20 to 3.08, n = 830
Not recorded as a finding: this platform holds no node for the endpoint
Meta-analysis showed that sertraline can prolong the IELT (changes of IELT, SMD 2.14, 95% CI 1.20 to 3.08, P <.00001; I 2 = 96%).
PMID:31169738 · one of two readings recorded this
patient sexual satisfaction rate
increases, SMD 2.20, 95% CI 1.57 to 2.84
Patients' sexual satisfaction rates were evaluated by 6, 7, and 8 items in the IIEF (0–15 points) among 3 studies, and meta-analysis showed that sertraline improved patients' sexual satisfaction rates (SMD 2.20, 95%CI 1.57 to 2.84, P <.00001).
PMID:31169738 · one of two readings recorded this
Patients' sexual satisfaction rate (IIEF items)
increases, SMD 2.20, 95% CI 1.57 to 2.84
Patients’ sexual satisfaction rates were evaluated by 6, 7, and 8 items in the IIEF (0–15 points) among 3 studies, and meta-analysis showed that sertraline improved patients’ sexual satisfaction rates (SMD 2.20, 95%CI 1.57 to 2.84, P <.00001).
PMID:31169738 · one of two readings recorded this
spouse sexual satisfaction rate
increases, SMD 2.27, 95% CI 1.44 to 3.09
Spouses' sexual satisfaction rates were evaluated by 6, 6, and 8 items in the IIEF (0–15 points) among 3 studies, and meta-analysis showed that sertraline improved spouses' sexual satisfaction rates (SMD 2.27, 95%CI 1.44 to 3.09, P <.00001).
PMID:31169738 · one of two readings recorded this
Spouses' sexual satisfaction rate (IIEF items)
increases, SMD 2.27, 95% CI 1.44 to 3.09
Spouses’ sexual satisfaction rates were evaluated by 6, 6, and 8 items in the IIEF (0–15 points) among 3 studies, and meta-analysis showed that sertraline improved spouses’ sexual satisfaction rates (SMD 2.27, 95%CI 1.44 to 3.09, P <.00001).
PMID:31169738 · one of two readings recorded this
anxiety score after treatment
decreases, SMD = -1.22, 95% CI: -1.96, -0.47
The result showed that the anxiety scores of patients treated with sertraline combined with CBT were significantly lower than those of the control group (SMD = −1.22, 95% CI: -1.96, -0.47, Figure 8(a)).
PMID:34992673 · one of two readings recorded this
Anxiety score after treatment (SMD)
decreases, SMD = -1.22, 95% CI: -1.96, -0.47
The result showed that the anxiety scores of patients treated with sertraline combined with CBT were significantly lower than those of the control group (SMD = −1.22, 95% CI: -1.96, -0.47, Figure 8(a)).
PMID:34992673 · one of two readings recorded this
depression score after treatment
decreases, SMD = -2.79, 95% CI: -3.64, -1.94
The result showed that after treatment, the depression score of patients treated with sertraline combined with CBT was significantly lower than that of the control group (SMD = −2.79, 95% CI: -3.64, -1.94, Figure 5).
PMID:34992673 · one of two readings recorded this
incidence of adverse reactions
decreases, OR = 0.43, 95% CI: 0.24, 0.75
The results showed that combined therapy achieved a lower incidence rate of adverse reactions in comparison with the control group (OR = 0.43, 95% CI: 0.24, 0.75, Figure 3(b)).
PMID:34992673 · both readings recorded this
Response rate for depression treatment
increases, OR = 5.07, 95% CI: 3.00, 8.58
The result showed that the effective rate of sertraline combined with CBT for depression was significantly higher than that in the control group (OR = 5.07, 95% CI: 3.00, 8.58, Figure 3(a)).
PMID:34992673 · one of two readings recorded this
response rate, incidence of adverse reactions, depression score, anxiety score and symptom self-rating scale score after treatment, meta-analytically pooled
increases, OR = 5.07, 95% CI: 3.00, 8.58
Not recorded as a finding: the comparison was against another active treatment
The result showed that the effective rate of sertraline combined with CBT for depression was significantly higher than that in the control group (OR = 5.07, 95% CI: 3.00, 8.58, Figure 3(a)).
PMID:34992673 · one of two readings recorded this
symptom self-rating scale score after treatment
decreases, SMD = -1.73, 95% CI: -3.19, -0.27
By using a random-effect model ((I2 = 98.4%, P ≤ 0.001), the result demonstrated that the combination therapy achieved lower symptom self-rating scale scores compared with the control group (SMD = −1.73, 95% CI: -3.19, -0.27, Figure 8(b)).
PMID:34992673 · one of two readings recorded this
Symptom self-rating scale score after treatment (SMD)
decreases, SMD = -1.73, 95% CI: -3.19, -0.27
By using a random-effect model ((I2 = 98.4%, P ≤ 0.001), the result demonstrated that the combination therapy achieved lower symptom self-rating scale scores compared with the control group (SMD = −1.73, 95% CI: -3.19, -0.27, Figure 8(b)).
PMID:34992673 · one of two readings recorded this
treatment response rate
increases, OR = 5.07, 95% CI: 3.00, 8.58
The result showed that the effective rate of sertraline combined with CBT for depression was significantly higher than that in the control group (OR = 5.07, 95% CI: 3.00, 8.58, Figure 3(a)).
PMID:34992673 · one of two readings recorded this
interleukin-10 (IL-10)
no effect, MD <0.01 (95% CI: -0.23, 0.23), p = 0.98, n = 124
The pooled effect indicated no significant difference between the sertraline and control groups, with an MD of <0.01 (95% CI: −0.23, 0.23; Z = 0.03, p = 0.98).
PMID:42646594 · one of two readings recorded this
interleukin-10 (IL-10), pooled serum concentration
no effect, MD <0.01 (95% CI: -0.23, 0.23; Z = 0.03), p = 0.98, n = 124
Not recorded as a finding: no outcome node exists for IL-10 in the closed outcome list; only interleukin-6 and tnf-alpha are represented
The pooled effect indicated no significant difference between the sertraline and control groups, with an MD of <0.01 (95% CI: −0.23, 0.23; Z = 0.03, p = 0.98).
PMID:42646594 · one of two readings recorded this
interleukin-6 (IL-6)
no effect, MD -1.06 (95% CI: -2.32, 0.19), p = 0.1, n = 235
The pooled analysis showed no statistically significant overall effect of sertraline, with a mean difference (MD) of −1.06 (95% CI: −2.32, 0.19; Z = 1.66, p = 0.10).
PMID:42646594 · one of two readings recorded this
Interleukin-6 (IL-6), pooled serum concentration
no effect, MD -1.06 (95% CI: -2.32, 0.19; Z = 1.66), p = 0.1, n = 235
The pooled analysis showed no statistically significant overall effect of sertraline, with a mean difference (MD) of −1.06 (95% CI: −2.32, 0.19; Z = 1.66, p = 0.10).
PMID:42646594 · one of two readings recorded this
serum/plasma interleukin-10 (IL-10) concentration, meta-analytically pooled
no effect
Not recorded as a finding: no CAT:outcome node exists for interleukin-10
Overall, the pooled results suggest that sertraline did not significantly alter circulating levels of IL-6, IL-10, or TNF-α across the included studies.
PMID:42646594 · one of two readings recorded this
TNF-α, pooled serum concentration
no effect, MD -0.84 (95% CI: -4.04, 2.37; Z = 0.51), p = 0.61, n = 96
The pooled result also disclosed no significant effect of sertraline, with an MD of −0.84 (95% CI: −4.04, 2.37; Z = 0.51, p = 0.61).
PMID:42646594 · one of two readings recorded this
tumor necrosis factor-alpha (TNF-α)
no effect, MD -0.84 (95% CI: -4.04, 2.37), p = 0.61, n = 96
The pooled result also disclosed no significant effect of sertraline, with an MD of −0.84 (95% CI: −4.04, 2.37; Z = 0.51, p = 0.61).
PMID:42646594 · one of two readings recorded this
Sources cited
1 paper
- Subject
- sertraline
- Findings
- 2
- Papers
- 1